Beacon utilizes an EEG neurobiomarker platform powered by machine learning to enhance clinical trial efficiency and optimize treatment strategies for neurological and psychiatric disorders. By providing quantitative assessments of brain activity, the platform enables precise dose selection and patient stratification, improving the likelihood of successful treatment outcomes.
Funding
$29.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinical trials for neurological and psychiatric disorders often suffer from inefficiencies due to subjective assessments and a lack of precise methods for dose selection and patient stratification. This can lead to increased costs, longer timelines, and a higher risk of failure in demonstrating treatment efficacy.
Solution
Beacon provides an EEG neurobiomarker platform that leverages machine learning to enhance clinical trial efficiency and optimize treatment strategies for neurological and psychiatric disorders. The platform offers quantitative assessments of brain activity, enabling precise dose selection and patient stratification. By understanding the relationship between drug PK/PD and brain activity, Beacon helps identify doses with optimal efficacy and safety profiles. The platform's capabilities improve the likelihood of successful treatment outcomes by identifying optimal patient populations and deploying quantitative endpoints.
Target Audience
Beacon's primary customers are biopharma companies, academic medical centers, and neurotechnology developers involved in clinical trials for neurological and psychiatric disorders.
Features
- EEG-based quantitative assessment of treatment impact on brain activity and sleep data
- PK/PD modeling to identify doses with optimal efficacy and safety profiles
- Population stratification to identify and select optimal patient cohorts
- Augmented EEG platform utilizing the Dreem Headband
- State-of-the-art machine learning algorithms for EEG analysis
- Clinico-EEG database for translational research
- Target engagement demonstration
- Quantitative endpoints for improved trial success